Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research.

Slides:



Advertisements
Similar presentations
Streatham & Clapham Health Renal Outreach Clinic
Advertisements

Chronic kidney disease
Proteinuria and Haematuria – an update Alex Heaton
CKD ML/LH What are people hoping to cover from the session today?
Algorithm Dr. Patrice Junod Clinique médicale l’Actuel This activity is supported by an educational grant from:
Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
DIABETES AND THE KIDNEYS
Progressive Chronic Kidney Disease Cherelle Fitzclarence August 2009.
CKD In Primary Care Dr Mohammed Javid.
Nephrology in General Practice Dr. M. Imran MBBS, MRCP(UK), MRCP (renal medicine), Post grad cert in clin Ed. Consultant Nephrologist MRCP Examiner ( Royal.
National Institute for Health and Clinical Excellence.
DM & CKD Dr. Shahrzad Shahidi Professor of Nephrology Isfahan University of Medical Sciences.
Cardiovascular Hot topics Dr Saqib Mahmud, MRCP(UK)
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
RENAL BLOOD TESTS WHAT DO THEY MEAN, WHERE TO GO FOR WHAT TO DO.
Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,
Ken Chow. What is haematuria?  Macroscopic Visible haematuria Pink or red  Microscopic Gold standard – Microscopy ○ Presence of >3 RBCs per high-powered.
Chronic Kidney Disease NICE Guidelines 2008 Dr Jennifer Kuo Dr Naeema Rashid Dr Shamita Das.
Chronic Kidney Disease Jacqueline Annand – CKD Nurse Mary Simpson – CKD Nurse Joyce Mackie – Pre Dialysis/Transplant liaison Sister.
Chronic Kidney Disease: A Silent Epidemic (Case Review) Naima Ogletree, MSN, APRN, BC Nephrology & Hypertension Henry Ford Health System.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Diabetic Nephropathy Case Presentations. UA (Urine Dipstick) Use as an initial screen for all patients Negative to trace proteinuria requires further.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
AKI and CKD: Top ten facts for primary care physicians
Clinical Biochemistry FAQ for GP Trainees Dr Mourad Labib Consultant Chemical Pathologist DGOH NHS Foundation Trust July 2009.
An update on chronic renal failure: follow-up and when to refer ? Assoc Prof Johan Rosman Renal Department Waitemata DHB
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
CASE 1. Donald is a 68 year-old man who is admitted to hospital via the Emergency Department one day, following a myocardial infarction. Subsequent investigation.
New Concepts in Chronic Kidney Disease Jonathan B. Jaffery, MD Assistant Professor of Medicine University of Wisconsin-Madison.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
Kreatinine Verklaard !? Introductie. At what level of creatinine does a 65-year-old diabetic, hypertensive white woman weighing 50 kilograms have chronic.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.
Blood pressure control in primary health care WORKSHOP
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Section 5: Configuration of healthcare to manage CKD.
Expert Systems in Renal Disease Kent Renal ServiceUniversity of KentSalford Hospital Chris Farmer Bernhard Klebe Jean IrvingDonal O’Donoghue Paul StevensRoger.
Dr M Sivalingam Renal Unit, Lister Hospital, Stevenage.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Chronic Kidney Disease SERVICE 6. Chronic Kidney Disease Stages 4-5 (GFR
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Project supported by A Package of Innovation for Managing kidney disease in primary care Registered Office: Nene Hall, Lynch Wood Park, Peterborough PE2.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
What is PD2010_023 Policy Directive from NSW DOH, 15th April 2010
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
Management of chronic kidney disease
Case 4: 65-year-old Man Newly Diagnosed, Has Other Health Issues Paul E. Sax, MD Clinical Director, Division of Infectious Diseases Brigham and Women’s.
CHRONIC KIDNEY DISEASE
Insulin Optimisation Workshop Theingi Aung & Claire Rowell.
Prescribing in cardiovascular disease By Jole Hannan Medicines Optimisation Pharmacist.
Sheffield Kidney Institute Global Kidney Academy CKD Micro-Lecture Epidemiology, Screening and Guidelines Professor Meguid El Nahas, PhD, FRCP Sheffield.
Cardiovascular complications in Chronic Kidney Disease Nihil Chitalia Consultant Nephrologist Epsom and St. Heliers’ University Hospital NHS trust - Hopes.
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
A. Evaluation point Hospitalization (10 or more days)
Section 4: Managing progression of CKD
Section 6: Management in primary care
Mansoura International Hospital Mansoura International Hospital
Multimorbidity and diabetes - what to do?
Chapter 1: CKD in the General Population
Chronic kidney disease and pre-dialysis
Chronic Kidney Disease in HIV Infection: An Urban Epidemic
MANAGING KIDNEY DISEASE IN PRIMARY CARE
Chapter 1: CKD in the General Population
Section 5: Configuration of healthcare to manage CKD
Multimorbidity and diabetes - what to do?
Presentation transcript:

Chronic Kidney Disease Workshop Maarten Taal Department of Renal Medicine Derby City General Hospital Derby Nephrology Research

Case #1 76 year male No previous illnesses Smoker 10/day PC: tiredness, some dyspnoea Examination: BP144/92; urine- + protein Serum creatinine 116  mol/l; Hb 10.5g/dL

Case #1 - Questions 1.What would you do next? 2.What is his eGFR? 3.Should he be referred to Nephrology?

Case #1 - Answers 1.What would you do next? –Urine protein:creatinine (1.8mg/mg) –eGFR 2.What is his eGFR? –56ml/min/1.73m 2 (CKD stage 3) 3.Should he be referred to Nephrology? –Yes

Case #2 23 year female No previous illnesses PC: tiredness; arthralgia in hands for 2 months Examination: BP132/78; urine: + protein Serum creatinine 63  mol/l ; Hb11.1g/dl

Case #2 - Questions 1.What would you do next? 2.What is her eGFR? 3.Should she be referred to Nephrology?

Case #2 - Answers 1.What would you do next? –Urine protein:creatinine (0.9mg/mg) –Lupus serology 2.What is her eGFR? –>60ml/min/1.73m 2 (CKD stage 1-2) 3.Should she be referred to Nephrology? –Yes

Case #3 81 year male Past Hx: Asthma; non-smoker “Well man’s clinic” BP128/76; urine: + protein Serum creatinine 114  mol/l ; eGFR 57; Hb11.1g/dl

Case #3 - Questions 1.What would you do next? 2.Should he be referred to Nephrology?

Case #3 - Answers 1.What would you do next? –Urine protein:creatinine (0.1mg/mg) –Previous creatinine value? (112 in 2001) 2.Should he be referred to Nephrology? –No –Recheck eGFR and urine in 6 months, annually if stable

Case #4 64 year female Past Hx: hypertension for 15y; smokes 15/day Annual health check: urine 2+ blood Rx trimethoprim BP 132/74; urine 2+ blood Serum creatinine 83  mol/l; eGFR>60

Case #4 - Questions 1.What would you do next? 2.Should he be referred to Nephrology?

Case #4 - Answers 1.What would you do next? –Send MSU for MC&S (negative) 2.Should he be referred to Nephrology? –No –Refer Urology

Case #5 76 year female Type 2 diabetes for 17 years Hypertension and diabetic nephropathy for 10 years Rx Irbesartan 300mg/day Annual review –Serum creatinine 221  mol/l –Urine: 2+ protein

Case #5 - Questions 1.What would you do next? 2.What is her eGFR? 3.Should she be referred to Nephrology?

Case #5 - Answers 1.What would you do next? –Estimated GFR –Urine protein:creatinine (2.3mg/mg) 2.What is her eGFR? –20ml/min/1.73m 2 (CKD stage 4) 3.Should she be referred to Nephrology? –Yes, immediately

Case #6 57y male Type 2 diabetes x 15 years Diabetic nephropathy, hypertension, OA Rx –Metformin 500mg tds –Lisinopril 40mg od –Aspirin 75mg od –Simvastatin 40mg nocte

Case #6 - Data Creatinine 245  mol/l; eGFR 28ml/min Corr calcium 2.24mmol/l Phosphate 2.16mmol/l Hb 9.8mg/dl Ferritin 47 (normal>30) B12 and folate normal

Case #6 - Questions What changes to medication? What interventions for high phosphate and PTH? What investigations and treatment for anaemia?

Case #6 - Answers What changes to medication? –Stop Metformin What interventions for high phosphate and PTH? –Phosphate binder –1-alfacalcidol once phosphate <1.6mmol/l What investigations and treatment for anaemia? –Clinical assessment to exclude GI bleeding –Intravenous iron –Erythropoeitin

A 55y male type 2 diabetic patient is started on Irbesartan 150mg/d for hypertension and proteinuria. The serum creatinine increases from 145 to 171  mol/l after 1 week. The most appropriate response is: a.No action required b.Discontinue the Irbesartan c.Reduce the dose of Irbesartan d.Repeat the creatinine measurement in 1 week e.Refer to a Nephrologist Case #7

A 55y male type 2 diabetic patient is started on Irbesartan 150mg/d for hypertension and proteinuria. The serum creatinine increases from 145 to 171  mol/l after 1 week. The most appropriate response is: a.No action required b.Discontinue the Irbesartan c.Reduce the dose of Irbesartan d.Repeat the creatinine measurement in 1 week e.Refer to a Nephrologist Case #7 - Answer

Case #8 56y male Type 2 diabetes for 9 years Hypertensive and obese Rx: amlodipine Annual screening: –BP143/90 –creatinine 103  mol/l ; eGFR >60 –Urine ACR 4.7 mg/  mol

Case #8 - Questions 1.What would you do next? 2.Should he be referred to Nephrology?

Case #8 - Answers 1.What would you do next? –Repeat urine ACR (6.3 mg/  mol) –Start treatment with ACEI or ARB; titrate to maximum dose –Control BP to <130/80 –Minimise cardiovascular risk –Weight loss 2.Should he be referred to Nephrology? –No –Review annually once optimised